Achieve Life Sciences (ACHV) Free Cash Flow (2010 - 2026)
Achieve Life Sciences (ACHV) posted Free Cash Flow of -$6.9 million for Q1 2026, up 61.51% on a QoQ basis from -$18.0 million in Q4 2025, and up 37.48% year-over-year from -$5.0 million in Q1 2025.
Achieve Life Sciences (ACHV) Free Cash Flow (2010 - 2026) Analysis & Trends
Achieve Life Sciences' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$6.9 million for Q1 2026.
- Quarterly Free Cash Flow rose 37.48% year-over-year to -$6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$45.3 million (down 27.48% YoY) and the FY2025 annual result came in at -$49.5 million, down 66.28% from the prior year.
- Free Cash Flow was -$6.9 million for Q1 2026 at Achieve Life Sciences, up from -$18.0 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$4.4 million in Q4 2023 and bottomed at -$18.0 million in Q4 2025.
- A 5-year average of -$8.7 million and a median of -$8.3 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 113.55% — and 2023, when it soared 60.78%.
- Achieve Life Sciences' Free Cash Flow stood at -$11.1 million in 2022, then surged by 60.78% to -$4.4 million in 2023, then sank by 110.27% to -$9.2 million in 2024, then slumped by 96.02% to -$18.0 million in 2025, then jumped by 61.51% to -$6.9 million in 2026.
- Business Quant data shows ACHV's Free Cash Flow at -$6.9 million in Q1 2026, -$18.0 million in Q4 2025, and -$11.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -354.95 Mn |
| 10 | Achieve Life Sciences | 326.16 Mn | 326.16 Mn | - | -6.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.93 Mn |
| Mar 31, 2026 | -6.93 Mn |
| Dec 31, 2025 | -18.01 Mn |
| Dec 31, 2025 | -18.01 Mn |
| Sep 30, 2025 | -11.29 Mn |
| Sep 30, 2025 | -11.29 Mn |
| Jun 30, 2025 | -9.11 Mn |
| Jun 30, 2025 | -9.11 Mn |
| Mar 31, 2025 | -11.09 Mn |
| Mar 31, 2025 | -11.09 Mn |
| Dec 31, 2024 | -9.19 Mn |
| Dec 31, 2024 | -9.19 Mn |
| Sep 30, 2024 | -10.37 Mn |
| Sep 30, 2024 | -10.37 Mn |
| Jun 30, 2024 | -4.92 Mn |
| Jun 30, 2024 | -4.92 Mn |
| Mar 31, 2024 | -5.29 Mn |
| Mar 31, 2024 | -5.29 Mn |
| Dec 31, 2023 | -4.37 Mn |
| Dec 31, 2023 | -4.37 Mn |